Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 15, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present at the Emerging Growth Conference on August 21, 2024

Company to Discuss Recent Mpox Developments as Well as Milestones Related to theBARDA Project NextGen Award for Its Next-generation COVID-19 Vaccine ATLANTA, GA, Aug. 15, 2024 (GLOBE NEWSWIRE) --...
August 08, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board

Strategic Appointment Enhances GeoVax’s Leadership and Expertise in Vaccine Development ATLANTA, GA, Aug. 08, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
August 06, 2024 16:00 ET | Source: GeoVax, Inc.

GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update

Awarded BARDA Project NextGen (PNG) contract to advance GeoVax’s multi-antigen vaccine candidate, GEO-CM04S1, into 10,000-participant randomized, comparative Phase 2b COVID-19 vaccine study BARDA PNG...
July 31, 2024 10:15 ET | Source: GeoVax, Inc.

Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq:...
July 31, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review

Company plans Phase 2 trial in first-recurrence head & neck cancer, in combination with immune checkpoint inhibitor ATLANTA, GA, July 31, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq:...
July 30, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Report Second Quarter 2024 Financial Results and Provide Corporate Update on August 6, 2024

GeoVax to Host Conference Call at 4:30 PM ET ATLANTA, GA, July 30, 2024 (GLOBE NEWSWIRE) -- GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and...
April 04, 2024 12:30 ET | Source: GeoVax, Inc.

GeoVax Presents Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine

Presentation Made During the 24th Annual World Vaccine Congress ATLANTA, GA, April 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company...
March 28, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress

ATLANTA, GA, March 28, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
March 12, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax to Present at the 36th Annual Roth Conference

ATLANTA, GA, March 12, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing immunotherapies and vaccines against cancers and infectious...
March 06, 2024 09:00 ET | Source: GeoVax, Inc.

GeoVax Achieves Milestone in Transition to Commercially Validated Manufacturing System

Manufacturing Process for Phase 3 and Commercial Production Being Developed for GeoVax MVA-Based Vaccines ATLANTA, GA, March 06, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc....

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right